Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease.

Authors:
Hartl L; Haslinger K; Angerer M; Semmler G; Semmler G and 17 more

Journal:
Hepatology

Publication Year: 2022

DOI:
10.1002/hep.32582

PMCID:
PMC9347407

PMID:
35596929

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Hepatology

Abbreviation: Hepatology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A global action agenda for turning the tide on fatty liver disease.
Lazarus JV; Mark HE; Allen AM and 44 more (2023) - Transparency Score: 3/6
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.
Leslie J; Hunter JE; Collins A and 15 more (2023) - Transparency Score: 3/6
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex wi…
Mizushima D; Takano M; Aoki T and 7 more (2023) - Transparency Score: 3/6
Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hep…
Gömer A; Klöhn M; Jagst M and 12 more (2023) - Transparency Score: 3/6
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
Juárez-Fernández M; Goikoetxea-Usandizaga N; Goikoetxea-Usandizaga N and 18 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST Dr. Simbrunner received grants from Gilead and AbbVie. Dr. Trauner consults for, is on the speakers' bureau for, and received grants from Falk, Intercept, Gilead, and MSD. He consults for and received grants from Alberio. He consults for BiomX, Boehringer Ingelheim, Genfit, Janssen, Novartis, Shire, Phenex, and Regulus. He received grants from Cymabay, Takeda, Alnylam, Ultragenyx, and AbbVie. He is the coinventor of patents on the medical use of 24‐norursodesoxycholic acid. Dr. Mandorfer consults for, advises, is on the speakers' bureau for, and received grants from AbbVie and Gilead. He consults for, advises, and is on the speakers' bureau for Collective Acumen and W.L. Gore & Associates."

Evidence found in paper:

"Medical Scientific Fund of the Mayor of the City of Vienna"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025